US 12,453,784 B2
Biologically inert fluid for use in the treatment of a CNS disorder
Steven S. Gill, Bristol (GB)
Assigned to NEUROCHASE INNOVATIONS LTD, Cardiff (GB)
Appl. No. 17/264,973
Filed by XCED LLP, London (GB)
PCT Filed Aug. 5, 2019, PCT No. PCT/GB2019/052187
§ 371(c)(1), (2) Date Feb. 1, 2021,
PCT Pub. No. WO2020/030892, PCT Pub. Date Feb. 13, 2020.
Claims priority of application No. 1812746 (GB), filed on Aug. 6, 2018.
Prior Publication US 2021/0260220 A1, Aug. 26, 2021
Int. Cl. A61K 48/00 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/46 (2006.01); A61M 5/14 (2006.01); A61M 5/158 (2006.01); A61P 21/00 (2006.01); A61P 25/08 (2006.01); A61P 25/28 (2006.01); A61P 43/00 (2006.01)
CPC A61K 48/0083 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01); A61K 47/46 (2013.01); A61M 5/1409 (2013.01); A61M 5/158 (2013.01); A61P 21/00 (2018.01); A61P 25/08 (2018.01); A61P 25/28 (2018.01); A61P 43/00 (2018.01); A61M 2210/0693 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating a CNS disorder, the method comprising administering a biologically inert fluid and a therapeutic agent to a patient in need thereof, wherein:
the therapeutic agent is infused into a brain of said patient via convection enhanced delivery (CED) using a catheter tip positioned into a subcortical white matter region of said brain, and
the biologically inert fluid is infused into the brain via CED using a catheter tip positioned into a deep white matter region that is deeper than the subcortical white matter region, such that the biologically inert fluid drives the therapeutic agent to a cerebral cortex region of said brain.